RT Journal Article
SR Electronic
T1 Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.18.21251437
DO 10.1101/2021.02.18.21251437
A1 Susan Yonemura
A1 Lindsay Hartson
A1 Taru Dutt
A1 Marcela Henao-Tamayo
A1 Raymond Goodrich
A1 Susanne Marschner
YR 2021
UL http://medrxiv.org/content/early/2021/02/20/2021.02.18.21251437.abstract
AB Background and Objective Convalescent plasma (CP) has been embraced as a safe therapeutic option for coronavirus disease 2019 (COVID-19) while other treatments are developed. However, transfusion-transmitted disease is a risk, particularly in regions with high endemic prevalence of transfusion-transmissible diseases. Pathogen reduction can mitigate this risk; thus, the objective of this study was to evaluate the effect of riboflavin and ultraviolet light (R+UV) pathogen reduction technology on the functional properties of CCP.Materials and Methods CCP units (n = 6) from recovered COVID-19 research donors were treated with R+UV. Pre- and post-treatment samples were tested for coagulation factor and immunoglobulin retention. Antibody binding to spike protein receptor binding domain (RBD), S1, and S2 epitopes of SARS-CoV-2 was assessed by ELISA.Neutralizing antibody (nAb) function was assessed by pseudovirus reporter viral particle neutralization (RVPN) assay and plaque reduction neutralization test (PRNT).Results Mean retention of coagulation factors was ≥ 70% while retention of immunoglobulins was 100%. Starting nAb titers were low, but PRNT50 titers did not differ between pre- and post-treatment samples. No statistically significant differences were detected in levels of IgG (P ≥ 0.3665) and IgM (P ≥ 0.1208) antibodies to RBD, S1, and S2 proteins before and after treatment.Conclusion R+UV PRT effects on coagulation factors were similar to previous reports, but no significant effects were observed on immunoglobulin concentration and antibody function. SARS-CoV-2 nAb function in COVID-19 convalescent plasma is conserved following R+UV PRT treatment.Competing Interest StatementS.Y. and S.M. are employees of Terumo Blood and Cell Technologies, the manufacturer of the pathogen reduction technology described in this article. L.H., T.D., M.H.D. and R.G. have no conflicts of interest to declare.Clinical TrialThis study was not a clinical trial; it was an in vitro study of human COVID-19 convalescent plasmaFunding StatementThis study was funded by Terumo Blood and Cell TechnologiesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:COVID-19 convalescent plasma was collected at Key Biologics under protocol "COLLECTION OF BLOOD COMPONENTS BY LEUKAPHERESIS FROM PATIENTS POST SARS-COV-2 INFECTION FOR SUPPORT OF RESEARCH," approved by Advarra IRB. Confirmation of ethics approval for CCP collection was provided to our research collaborators by Edward P. Scott, MD, Principal Investigator at Key Biologics. CCP unit ID numbers are not traceable to donor identity outside of Key Biologics. Ethical approval for the study was provided by the Colorado State University Research Integrity & Compliance Review Office, Fort Collins, CO, under the "Indications against Highly Pathogenic Agents for a Transportable Pathogen Reduction and Blood Safety System for Whole Blood, Platelets and Plasma" protocol. Per the IRB review it was determined that the activity did not meet the requirements of the federal definition of human subject research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A